These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33431785)

  • 1. Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus.
    Nishioka S; Ishimura T; Endo T; Yokoyama N; Ogawa S; Fujisawa M
    Ann Transplant; 2021 Jan; 26():e926476. PubMed ID: 33431785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.
    Ishida H; Ogura G; Uehara S; Takiguchi S; Nakagawa Y; Hamano N; Koizumi M; Wada T; Fukagawa M; Nakamura M
    Clin Exp Nephrol; 2020 Mar; 24(3):268-276. PubMed ID: 31792639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
    Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
    Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
    Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
    Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
    Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
    Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
    Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
    Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation.
    Tomita Y; Uehara S; Takiguchi S; Nakamura M
    Transplant Proc; 2023 May; 55(4):792-796. PubMed ID: 37100735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
    De Simone P; Saliba F; Dong G; Escrig C; Fischer L
    Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of everolimus in maintenance kidney transplant patients in the real-world setting: results from a 2-year post-marketing surveillance study in Japan.
    Hayase N; Yamada M; Kaneko S; Watanabe Y
    Clin Exp Nephrol; 2021 Jun; 25(6):660-673. PubMed ID: 33575935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.